8 November 2022 / godz. 13:49
We are pleased to announce that on 08.11.2022 a Scientific Cooperation Agreement was signed between the M. Sklodowska-Curie National Cancer Institute Gliwice Branch and the consortium: Acellmed Sp. z o.o. and Silesian Park of Medical Technology Kardio-Med Silesia. The scientific cooperation will consist of verifying the therapeutic activity and specificity of action of the anti-acute myeloid leukemia (AML) drug being developed by the Acellmed – Silesian Park of Medical Technology Kardio-Med Silesia consortium on leukemic cells of AML patients treated at the M. Skłodowska-Curie National Cancer Institute Gliwice Branch.
The project to develop a drug against AML: “personalized liposome-based therapy for acute myeloid leukemia (OBS/AML) based on small inhibitory RNAs” is funded by the Office of the Marshal – Silesian Center for Entrepreneurship within the framework of the WSL ROP 1.2 competition.
Copyright 2023. Kardio-Med Silesia. All rights reserved.